Axolt Launches Brain Supplement to Combat Post-Pandemic Burnout Crisis
Axoltannounced the launch of its revolutionary brain health supplement designed specifically for high-performing professionals experiencing mental fatigue, focus issues, and cognitive decline.
Research reveals that psychological distress now affects 50% of working professionals globally¹, with studies demonstrating measurable cognitive impairment during high-stress periods². For ambitious professionals, these statistics reflect a fundamental threat to sustained mental performance.
'Our modern brain is chronically overloaded and undernourished,'said Martin Valovsky, Axolt founder.'We created Axolt because most cognitive supplements offer temporary stimulation when high performers need comprehensive brain nutrition that supports stress response and peak cognitive function.'
A Different Approach
Unlike conventional nootropics that rely on caffeine and synthetic stimulants, Axolt delivers a blend of47 science-backed ingredientstargeting cognitive resilience and sustained mental performance. The formula combines stress-supporting adaptogens, neuroprotective polyphenols, and brain-supporting nutrients to support focus, memory, and mental energy without crashes.
'Mental clarity and focus aren't optional, they're the difference between winning and losing,'said Andrew Bustamante, former CIA intelligence officer and Axolt user.'That's why I drink Axolt daily.'
Availability
Available as a berry-flavored daily supplement for professionals facing high cognitive demands onthe Axoltwebsite.
*The statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Sources: ¹ Centre for Mental Health. COVID-19 and the Nation's Mental Health: A Review of the Evidence Published So Far. 2024. ² PMC study on work-related stress and cognitive functioning during COVID-19.
To request interviews, samples, or expert commentary, contact:[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News24
5 hours ago
- News24
5 tips for radiant skin throughout the seasons
A good skincare routine is beneficial all year round. Rule number one is applying sunscreen every single day and ample moisturisation to maintain radiant skin. Be your own goals with these beauty secrets and skin saviours: 1. Heat shield Protect your melanin magic from the sun's harsh rays by applying a sunscreen daily – from winter to summer. Apply five minutes after your moisturiser, as the last step to your beauty regime. Make sure it's an SPF50 or higher for the best protection time. 2. Hydration station Quench your skin's thirst by choosing a moisturiser that contains ingredients designed to lock in moisture – like hyaluronic acid and glycolic acid. Slather on your moisturiser when your skin is damp to help retain hydration. 3. Glow up Restore the glow and radiance in your skin with products infused with vitamin C – a brightening super ingredient. Pop a vitamin C mask on your face for 15 minutes once a week to bring your skin back to life! 4. Even tone Even out discoloration by applying a treatment serum that will penetrate deeper into your skin to help reverse the reaction that causes dark marks. Serums that contain glycolic acid, retinol, kojic acid and vitamin C will increase cell turnover and rejuvenate your skin tone and complexion. 5. Soft and smooth Cleansing and mild exfoliation can give your skin a smoother, more radiant appearance by removing dead skin cells on the surface. Massage face oils into your skin at night to prevent flaking and dry patches and keep it silky soft.
Medscape
9 hours ago
- Medscape
Prenatal Hypothyroxinaemia Tied to Gestational Diabetes Risk
TOPLINE: Pregnant women with decreased levels of free thyroxine (FT 4 ) and isolated hypothyroxinaemia (defined as having normal thyroid-stimulating hormone [TSH] and low FT 4 concentrations) had a substantially higher risk of developing gestational diabetes, challenging the long-held assumptions that subclinical hypothyroidism and thyroid autoimmunity are risk factors for the condition. METHODOLOGY: Researchers performed a meta-analysis of individual participant data to investigate the association between maternal thyroid function and the risk for gestational diabetes involving 63,548 pregnant women (median age, 29 years; overall mean prevalence of gestational diabetes, 4.7%) from 25 prospective cohorts worldwide, including both published and unpublished studies. Exposures comprised thyroid dysfunction (subclinical hypothyroidism, isolated hypothyroxinaemia, overt hyperthyroidism, and subclinical hyperthyroidism) and measurements of thyroid function tests for TSH, FT 4 , free triiodothyronine (FT 3 ), total T 3 , FT 3 :FT 4 ratio, and antibodies indicative of an autoimmune thyroid disease. , free triiodothyronine (FT ), total T , FT :FT ratio, and antibodies indicative of an autoimmune thyroid disease. The primary outcome was the occurrence of gestational diabetes (as defined for each cohort). Secondary outcomes included serum glucose measurements during an oral glucose tolerance test (at 24-28 weeks of gestation), the homeostatic model assessment for insulin resistance, and fasting insulin measurements. TAKEAWAY: In a meta-analysis of 17 cohorts involving 45,900 participants, isolated hypothyroxinaemia was associated with a higher risk for gestational diabetes than euthyroidism (absolute risk, 6.5% vs 3.5%; adjusted odds ratio, 1.52; P = .0017). According to a meta-analysis of 22 cohorts, lower FT 4 concentrations were independently associated with a higher risk for gestational diabetes; another meta-analysis of 11 cohorts revealed that higher FT 3 concentrations and a higher FT 3 :FT 4 ratio were also associated with a higher risk for gestational diabetes (P < .0001 for all). concentrations were independently associated with a higher risk for gestational diabetes; another meta-analysis of 11 cohorts revealed that higher FT concentrations and a higher FT :FT ratio were also associated with a higher risk for gestational diabetes (P < .0001 for all). Lower FT 4 concentrations were associated with higher glucose values during an oral glucose tolerance test, with this association being more prominent in individuals without obesity (BMI < 26); lower FT 4 concentrations were also associated with greater insulin resistance (P < .0001). concentrations were associated with higher glucose values during an oral glucose tolerance test, with this association being more prominent in individuals without obesity (BMI < 26); lower FT concentrations were also associated with greater insulin resistance (P < .0001). Subclinical hypothyroidism and autoimmune thyroid disease showed no association with the risk for gestational diabetes. IN PRACTICE: "The absence of association between subclinical hypothyroidism and gestational diabetes risk does not support universal screening and treatment of maternal subclinical hypothyroidism to improve gestational diabetes risk," the author of a commentary wrote. SOURCE: This study was led by Joris A. J. Osinga, MD, Academic Center for Thyroid Diseases, Erasmus University Medical Center, Rotterdam, the Netherlands. It was published online on June 30, 2025, The Lancet Diabetes & Endocrinology. LIMITATIONS: The included studies showed heterogeneity in the definition of gestational diabetes, leading to non-differential misclassification, limiting power and generalisability. The exclusion of participants using thyroid-affecting medications may have created a healthier study population compared with the real-world population. The reliability of FT 3 and FT 4 assays was potentially compromised by increased concentrations of thyroid-binding proteins during pregnancy. DISCLOSURES: This study was supported by the Netherlands Organization for Scientific Research, ZonMw, and the European Union Horizon 2020 Program. Some authors declared receiving honoraria, travel support, and financial research funding; compensation for lecturing or educational events; and fees for serving on data-monitoring or advisory boards as well as having other ties with various pharmaceutical and healthcare organisations. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Bloomberg
15 hours ago
- Bloomberg
Novartis Wins Approval for First Malaria Treatment for Babies
Novartis AG won regulatory approval for the first medicine designed for babies with malaria, the latest development in the global fight against the mosquito-borne disease. The Swiss drugmaker said the country's agency Swissmedic approved a new formulation of its drug Coartem to treat infants weighing less than 4.5 kilograms (9.9 pounds), according to a statement Tuesday. The company expects approval from eight countries in Africa to follow.
